Design of novel F-ATP synthase inhibitors of mycobacterium tuberculosis

F1FO ATP synthase of Mycobacterium tuberculosis is an attractive and intensively-studied drug target. Adenosine triphosphate (ATP) is necessary for cell growth and is vital for cell survival, especially in the case of dormant Mycobacterium. In 2012, an inhibitor of F1FO ATP synthase, Bedaquiline (BD...

Full description

Saved in:
Bibliographic Details
Main Author: Hotra, Adam
Other Authors: Gerhard Gruber
Format: Theses and Dissertations
Language:English
Published: 2018
Subjects:
Online Access:http://hdl.handle.net/10356/75829
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
Language: English
id sg-ntu-dr.10356-75829
record_format dspace
spelling sg-ntu-dr.10356-758292021-03-20T13:12:47Z Design of novel F-ATP synthase inhibitors of mycobacterium tuberculosis Hotra, Adam Gerhard Gruber Roderick Wayland Bates Interdisciplinary Graduate School (IGS) DRNTU::Science::Biological sciences F1FO ATP synthase of Mycobacterium tuberculosis is an attractive and intensively-studied drug target. Adenosine triphosphate (ATP) is necessary for cell growth and is vital for cell survival, especially in the case of dormant Mycobacterium. In 2012, an inhibitor of F1FO ATP synthase, Bedaquiline (BDQ) was approved for the treatment of tuberculosis (TB). Despite promising efficacy, BDQ was found to have several adverse effects and therefore is used solely for the treatment of multiple drug-resistant tuberculosis (MDR-TB). This suggests the need for a more viable drug targeting the respiratory chain. A new drug target in F1FO ATP synthase was proposed; a 13 amino acid-long loop γ165–178 at the interface of the c-ring and subunit γ. This loop is unique to Mycobacterium and enables specific compound binding without affecting the human F1FO ATP synthase. To date, no high-definition structure of the Mycobacterium F1FO ATP synthase is present in literature, and hence to study it, a homology model was built. With this model, 1.5 million compounds were docked using Maestro suite (Schrödinger). The 81 best scoring compounds were tested for growth inhibition and one compound (compound 6) inhibited non-pathogenic M. smegmatis with an IC50 11 μM and M. bovis BCG with an IC50 of 40 μM. Furthermore, compound 6 blocked ATP synthesis and hydrolysis in the inverted membrane vesicles assay. Hence, it was confirmed that compound 6 binds to the F1FO ATP synthase as predicted. Additionally, the hydrolysis rate, and amount of ATP synthetized between wild-type vesicles and Δγ166-179 mutant vesicles was compared. Vesicles with the deletion of the γ166-179 loop increased the ATP hydrolysis rate. Interestingly ATP synthesis dropped by 50%. These results suggest that γ166-179 loop plays an important role in the coupling between the c-ring and the central stalk. Moving forward, compound 6 and a series of analogs were synthesized for lead optimization based on the model of the docked compound to the F1FO ATP synthase. Doctor of Philosophy (IGS) 2018-06-18T12:22:58Z 2018-06-18T12:22:58Z 2018 Thesis Hotra, A. (2018). Design of novel F-ATP synthase inhibitors of mycobacterium tuberculosis. Doctoral thesis, Nanyang Technological University, Singapore. http://hdl.handle.net/10356/75829 10.32657/10356/75829 en 183 p. application/pdf
institution Nanyang Technological University
building NTU Library
continent Asia
country Singapore
Singapore
content_provider NTU Library
collection DR-NTU
language English
topic DRNTU::Science::Biological sciences
spellingShingle DRNTU::Science::Biological sciences
Hotra, Adam
Design of novel F-ATP synthase inhibitors of mycobacterium tuberculosis
description F1FO ATP synthase of Mycobacterium tuberculosis is an attractive and intensively-studied drug target. Adenosine triphosphate (ATP) is necessary for cell growth and is vital for cell survival, especially in the case of dormant Mycobacterium. In 2012, an inhibitor of F1FO ATP synthase, Bedaquiline (BDQ) was approved for the treatment of tuberculosis (TB). Despite promising efficacy, BDQ was found to have several adverse effects and therefore is used solely for the treatment of multiple drug-resistant tuberculosis (MDR-TB). This suggests the need for a more viable drug targeting the respiratory chain. A new drug target in F1FO ATP synthase was proposed; a 13 amino acid-long loop γ165–178 at the interface of the c-ring and subunit γ. This loop is unique to Mycobacterium and enables specific compound binding without affecting the human F1FO ATP synthase. To date, no high-definition structure of the Mycobacterium F1FO ATP synthase is present in literature, and hence to study it, a homology model was built. With this model, 1.5 million compounds were docked using Maestro suite (Schrödinger). The 81 best scoring compounds were tested for growth inhibition and one compound (compound 6) inhibited non-pathogenic M. smegmatis with an IC50 11 μM and M. bovis BCG with an IC50 of 40 μM. Furthermore, compound 6 blocked ATP synthesis and hydrolysis in the inverted membrane vesicles assay. Hence, it was confirmed that compound 6 binds to the F1FO ATP synthase as predicted. Additionally, the hydrolysis rate, and amount of ATP synthetized between wild-type vesicles and Δγ166-179 mutant vesicles was compared. Vesicles with the deletion of the γ166-179 loop increased the ATP hydrolysis rate. Interestingly ATP synthesis dropped by 50%. These results suggest that γ166-179 loop plays an important role in the coupling between the c-ring and the central stalk. Moving forward, compound 6 and a series of analogs were synthesized for lead optimization based on the model of the docked compound to the F1FO ATP synthase.
author2 Gerhard Gruber
author_facet Gerhard Gruber
Hotra, Adam
format Theses and Dissertations
author Hotra, Adam
author_sort Hotra, Adam
title Design of novel F-ATP synthase inhibitors of mycobacterium tuberculosis
title_short Design of novel F-ATP synthase inhibitors of mycobacterium tuberculosis
title_full Design of novel F-ATP synthase inhibitors of mycobacterium tuberculosis
title_fullStr Design of novel F-ATP synthase inhibitors of mycobacterium tuberculosis
title_full_unstemmed Design of novel F-ATP synthase inhibitors of mycobacterium tuberculosis
title_sort design of novel f-atp synthase inhibitors of mycobacterium tuberculosis
publishDate 2018
url http://hdl.handle.net/10356/75829
_version_ 1695706226164236288